Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis

Farnia, Vahid; Shakeri, Jalal; Tatari, Faezeh; Juibari, Toraj Ahmadi; Yazdchi, Katayoun; Bajoghli, Hafez; Brand, Serge; Abdoli, Nasrin; Aghaei, Abbas

doi:10.3109/00952990.2013.861843

Cited by 37 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of clinical trials has been too low to help formulate a comprehensive manual to be used by the therapists [ 34 – 38 ]. In the present study, Risperidone and Olanzapine had the highest frequency of use of all antipsychotics, which can partly be the result of the current clinical trials indicating the positive effects of Risperidone in treating MIP [ 39 ]. These drugs are effective in restoring the weight, which patients considerably lost because of methamphetamine-induced appetite loss and hyperactivity.…”

Section: Discussionmentioning

confidence: 92%

Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients

et al. 2016

View full text Add to dashboard Cite

BackgroundOver the past few years, methamphetamine-induced psychosis (MIP) has increased in Iran, accounting for a significant percentage of psychiatry hospital admissions. The present study was conducted with an aim to investigate clinical symptoms, and course and treatment methods of MIP inpatients in Shafa Psychiatry Hospital in northern Iran.MethodsParticipants were 152 MIP inpatients. Brief Psychiatric Rating Scale (BPRS) subscales of suspiciousness, unusual thought content; hallucinations and hostility were used to measure psychiatric symptoms. Data regarding suicide and homicide and violence were also obtained through interviews with the inpatients and their family. Based on their lengths of recovery time, the inpatients were categorized into 3 clinical groups. These inpatients received their usual treatments and were monitored for their psychiatric symptoms and clinical course of illness. The data were analyzed by descriptive statistics.ResultsThe most frequent psychiatric symptoms were violence (75.6 %), intimate partner violence (61.2 %), delusions of persecution (85.5 %), delusions of reference (38.5 %), delusions of grandiosity (32.9 %), delusions of infidelity (30.2 %), auditory hallucinations (51.3 %), visual hallucinations (18.4 %), suicidal thoughts (14.5 %), homicidal thoughts (3.9 %), suicide attempts (10.5 %) and homicide attempts (0.7 %). Recovery from psychotic symptoms in 31.6 % of the inpatients took more than one month. 46.1% of the inpatients were treated with Risperidone and 37.5 % with Olanzapine. Persecutory delusion and auditory hallucination were the most frequent persistent psychotic symptoms. 20.8 % of the inpatients with duration of psychosis more than one month were treated with electroconvulsive therapy (ECT) along with antipsychotics.ConclusionAll forms of violence are highly frequent in MIP inpatients. Our finding agrees with many other studies suggesting that recovery from MIP can take more than a month. Initial promising findings were found regarding the efficacy of Electroconvulsive therapy in MIP patients.

show abstract

Section: Discussionmentioning

confidence: 92%

Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Risperidone was significantly superior in terms of positive symptoms compared to aripiprazole. The advantages of aripiprazole vs. risperidone in treating negative symptoms were not significant [49]. In another study aripiprazole (10-15 mg) and risperidone (2-4 mg) did not differ in terms of their good antipsychotic efficacy (n = 42).…”

Section: Schizophrenia and Methamphetamine-associated Psychosis (Map)mentioning

confidence: 90%

Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings

Härtel-Petri¹,

Krampe-Scheidler

Braunwarth

et al. 2017

Pharmacopsychiatry

View full text Add to dashboard Cite

The increasing abuse of the street drug crystal meth (methamphetamine) in many countries worldwide has resulted in a growing demand to treat patients who have acquired a methamphetamine-related disorder. The results of a systematic literature search which led to the consensus-based recommendations by the Working Group of the German Agency for Quality in Medicine (Ärztliches Zentrum für Qualität in der Medizin - ÄZQ) are presented. Pharmacological treatments were reviewed in 58 out of the 103 publications included. They were mainly randomized controlled trials (RCT). Despite increased research activities, none of the medications studied demonstrated a convincing and consistent effect on abstinence rates, despite some having an impact on craving and retention rates or symptom control. In addition, as yet there is no sufficient evidence available for dopamine analogue treatment ("substitution") after the initial withdrawal-period. Methamphetamine-related, post-acute persistent or comorbid syndromes such as methamphetamine-associated psychosis (MAP), depressive syndromes, anxiety, and sleep disorders are usually treated in a symptom-oriented manner. Risks of interactions with methamphetamine have to be taken in account when prescribing medications with doubtful efficacy. Further research is warranted.

show abstract

“…As an addictive psychostimulant drug, methamphetamine use is a new health concern in Iran but a few studies have targeted treating methamphetamine-associated psychosis (MAP) with antipsychotic medications in Iran and around the world (1-25). …”

Section: Introductionmentioning

confidence: 99%

Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study

Samiei

Vahidi

Rezaee

et al. 2016

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

BackgroundDifferent studies have suggested that antipsychotic medications of the first generation have better effectiveness for the treatment of psychotic symptoms compared with antipsychotic medications of the second generation.ObjectivesThe current study was the first pilot study in Iran that compared Haloperidol with Risperidone in the treatment of positive symptoms of psychosis among a group of methamphetamine-dependent patients.Materials and MethodsThis randomized clinical trial was designed and conducted in 2012. Overall, 44 patients who met the diagnostic and statistical manual of mental disorders, fourth edition-text revised (DSM.IV-TR) criteria for methamphetamine-associated psychosis (MAP) and were hospitalized at Razi psychiatric hospital in Tehran were selected. Patients (1: 1) were randomly divided to two groups. Overall, 22 subjects received Haloperidol (5 - 20 mg) and 22 subjects received Risperidone (2 - 8 mg). All subjects were assessed at baseline, during three consecutive weeks of treatment and one week after treatment (i.e., follow-up). Scale of assessment of positive symptoms (SAPS) was completed for each subject.ResultsThe study findings indicated that both Haloperidol (< 0.05) and Risperidone (< 0.05) were similarly applicable in the treatment of MAP but no differential effectiveness was found between the two medications. The treatment effects of both medications increased in the first two weeks of treatment and remained stable in the second two weeks.ConclusionsRisperidone and Haloperidol are two effective antipsychotic medications for the treatment of positive symptoms of MAP but other aspects of these two neuroleptic medications such as the long-term treatment effects should be studied. Further studies with more samples and longer follow-ups are suggested.

show abstract

Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis

Cited by 37 publications

References 13 publications

Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients

Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients

Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings

Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study

Contact Info

Product

Resources

About